Exploring the SPARAGMOS Study Protocol: review of a high-dose cabergoline interventional trial in microprolactinomas
- 3 September 2026
- journal article
- review article
- Published by Taylor & Francis in Endocrine Research
- Vol. 51 (4) , 250-261
Abstract
Prolactinoma is the most common functional pituitary tumor, accounting for up to 40% of pituitary adenomas. Dopamine agonists (DA) are usually the treatment of choice, with cabergoline (CAB) genera...Keywords
This publication has 65 references indexed in Scilit:
- Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenomaPituitary, 2025
- Cardiometabolic effects of hypoprolactinemiaReviews in Endocrine and Metabolic Disorders, 2024
- The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functionsPituitary, 2024
- Quality of life in Prolactinoma: A systematic reviewPituitary, 2024
- How to manage intolerance to dopamine agonist in patients with prolactinomaPituitary, 2023
- Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCTOsteoporosis International, 2022
- Do nothing but observe microprolactinomas: when and how to replace sex hormones?Pituitary, 2020
- Surgery for prolactinomas: a better choice?Pituitary, 2019
- Dopamine agonists in prolactinomas: when to withdraw?Pituitary, 2019
- Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawalPituitary, 2017